Alpha-MSH vs Thymosin Beta-4

Melanocortin peptide; activates MC1R (pigmentation/anti-inflammatory), MC3R (energy balance), MC4R (appetite); suppresses NF-κB and pro-inflammatory cytokines

α-Melanocyte-stimulating hormone (α-MSH) is an endogenous 13-amino-acid peptide derived from proteolytic processing of proopiomelanocortin (POMC) that acts through melanocortin receptors (MC1R–MC5R), with biological roles including skin pigmentation, anti-inflammatory signaling, thermoregulation, and energy homeostasis. Its anti-inflammatory actions are mediated principally through MC1R and MC3R activation, leading to inhibition of NF-κB-dependent cytokine production, reduction of pro-inflammatory mediators including IL-1β and TNF-α, and modulation of leukocyte activity in both peripheral and central nervous system compartments. Research published in the Annals of the New York Academy of Sciences has characterized the mechanisms of α-MSH's anti-inflammatory activity in vivo and in vitro, and subsequent work has described new insights into its immunomodulatory functions and therapeutic potential in inflammatory conditions. α-MSH is a research compound with no FDA approval for any indication; no human clinical trials have established safety or efficacy for exogenous α-MSH administration in anti-inflammatory, neuroprotective, or other therapeutic contexts. Alpha-MSH and the melanocortin peptide family α-MSH is the prototype endogenous ligand for the melanocortin receptor family — five receptors (MC1R–MC5R) with distinct tissue distribution and functions. The pharmacological development of synthetic melanocortin analogues has produced several clinically and commercially relevant compounds derived from or inspired by α-MSH: Melanotan I (afamelanotide, MC1R-selective, approved as Scenesse for erythropoietic protoporphyria), Melanotan II (non-selective, superpotent, never approved; extensively used in research), and PT-141/bremelanotide (cyclized Melanotan II analogue, FDA-approved as Vyleesi for female hypoactive sexual desire disorder via MC3R/MC4R). α-MSH itself serves as the structural reference point for this lineage — the pharmacophore binding sequence (His-Phe-Arg-Trp) shared by all active melanocortin analogues is derived from α-MSH residues 6–9. Appetite regulation and obesity research: α-MSH's role in energy homeostasis is mediated through MC4R activation in the hypothalamus, where it acts as an endogenous satiety signal opposing the appetitive effects of AgRP (agouti-related protein). Loss-of-function MC4R mutations are the most common monogenic cause of severe early-onset obesity, establishing the α-MSH/MC4R pathway as a validated target for pharmacological weight management. Setmelanotide (Imcivree), an MC4R agonist, is FDA-approved for obesity caused by MC4R pathway deficiency mutations (POMC deficiency, PCSK1 deficiency, leptin receptor deficiency) — a direct pharmacological descendant of the α-MSH mechanism.

Sequesters G-actin monomers via its WH2 domain, regulating actin dynamics and cell migration. Upregulates metalloproteinases and growth factors for tissue remodeling. Promotes cardiomyocyte survival and angiogenesis post-injury.

Thymosin beta-4 (Tb4) is an endogenous 43-amino-acid protein ubiquitously expressed in mammalian tissues, best characterized for its role in G-actin sequestration, cell migration promotion, and tissue repair signaling across multiple organ systems. Tb4 exerts reparative effects by upregulating angiogenesis, modulating inflammation, and generating the anti-fibrotic tetrapeptide Ac-SDKP through enzymatic cleavage; preclinical models in cardiac, renal, and musculoskeletal tissue have demonstrated measurable regenerative outcomes following exogenous administration. Published literature supports anti-fibrotic activity in animal models of renal fibrosis and cardiovascular injury, and the Tb4-Ac-SDKP pathway has been characterized as a plausible target in fibrosis biology; however, clinical translation has been limited, with a Phase 2 cardiac repair trial that did not demonstrate efficacy sufficient to advance to Phase 3. Exogenous thymosin beta-4 has no FDA approval for any indication; it is available only as a research compound, and the substantial gap between preclinical findings and human clinical outcomes represents an important limitation of the current evidence base. Thymosin beta-4 vs TB-500 TB-500 is a commercial label used for synthetic thymosin beta-4 in the peptide research market. The underlying compound is the same 43-amino-acid sequence as endogenous Tb4; "TB-500" originated as a brand name from veterinary product contexts and has since become the predominant research market name for synthetic thymosin beta-4. When research suppliers, athletes, or forum communities reference TB-500, they are referring to synthetic Tb4 — the same compound profiled here. The TB-500 label is commonly associated with injectable research peptide use; the thymosin beta-4 label is associated with the biochemical and medical literature. Some suppliers sell "TB-4 Frag" (the Ac-SDKP tetrapeptide fragment), which is a distinct, smaller molecule derived from enzymatic cleavage of Tb4, not the full-length thymosin beta-4 protein. Thymosin beta-4 dosage in research contexts: Research protocols described in preclinical literature and anecdotal human use reports typically reference doses in the range of 2–5 mg per injection, administered subcutaneously or intramuscularly, with a loading phase of 2–4 injections per week followed by a maintenance phase of 1–2 injections per week. These dosage figures are derived from research compound use and veterinary contexts, not from FDA-approved human clinical protocols — no approved human dosing exists. The Phase 2 cardiac repair trial that administered intravenous Tb4 used significantly different dose and route parameters. Thymosin beta-4 is available only as a research compound; it is not FDA-approved for any human indication and is not available through licensed prescription channels.